三重靶点 incretin 药物 Retatrutide 在肥胖相关膝关节骨关节炎中的疗效
Triple-Target Incretin Drug Kills Knee Osteoarthritis Pain in Obesity
Retatrutide 在 TRIUMPH-4 试验中显著减轻了肥胖相关膝关节骨关节炎患者的疼痛和功能障碍,同时体重减轻超过 25%。该药物通过刺激 GLP-1、胰高血糖素和 GIP 受体,显示出比单作用 GLP-1 药物更显著的减重效果。
研究显示,Retatrutide在减轻膝关节骨关节炎疼痛和改善功能方面效果显著,且伴有显著的体重减轻。
— Retatrutide also goes GLP-1 drugs one better for weight loss
by John Gever, Contributing Writer, MedPage Today
November 8, 2026 • 4 min read
ORLANDO -- The investigational obesity drug retatrutide was highly effective in reducing pain and improving disability in knee osteoarthritis (OA) associated with obesity, according to the TRIUMPH-4 trial.
Among patients in the study -- a follow-up to the TRIUMPH-1 study reported earlier this year -- pain scores on the Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) assessment declined by more than 4.4 points with retatrutide, versus a 2.43-point decrease with placebo, according to Thomas Conaghan, MBBS, PhD, of the University of Leeds in England.
Patients in TRIUMPH-4 on retatrutide lost more than one-quarter of their body weight after 68 weeks, Conaghan reported at the American College of Rheumatology annual meeting. The findings, along with a recap of TRIUMPH-1, were published simultaneously in the New England Journal of Medicine (NEJM).
Retatrutide is a triple threat against obesity and metabolic syndrome: not only does it stimulate the now familiar glucagon-like peptide-1 (GLP-1) receptor, but also receptors for glucagon itself as well as glucose-dependent insulinotropic polypeptide (GIP). Previous trials have shown that this added oomph leads to sharper weight losses than typically seen with single-action GLP-1 drugs such as semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) -- which in turn have prompted consumers to seek out retatrutide by any means necessary.
But because excessive body weight is a well-recognized contributor to OA pain and disability, weight-loss drugs are increasingly seen as an easy-to-access and potentially disease-modifying OA treatment. As it happens, the ACR has just released new guidelines on OA management that put even more emphasis than before on weight loss.
This wave of studies also may draw more attention to the phenomenon of "metabolic osteoarthritis," seen as clinically and etiologically distinct from "regular" OA that is presumed to stem from injury, either traumatic or gradual.
Conaghan didn't discuss exactly how retatrutide might affect OA pain, and the larger group of NEJM authors spent only a couple of sentences on it. "Weight reduction leads to decreased loading on the knee, and the level of load reduction appears to be a multiple of the actual weight lost," they wrote. "Some data suggest that reduction in adipose tissue may decrease systemic inflammatory mediators, findings that hint that GLP-1 receptor agonists may provide anti-inflammatory activity."
Beyond that, though, the group punted, calling for "further studies" on the mechanisms underlying OA pain and its reduction, as well as on retatrutide's potential as an actual disease-modifying OA therapy. A key point will be whether it helps metabolically normal OA patients without causing unhealthy weight loss.
Conaghan and colleagues randomized 445 patients with obesity (defined as BMI >27) and knee OA, from the U.S., Canada, Mexico, Australia, and Spain, assigning them in equal numbers to three arms: placebo or 9 or 12 mg retatrutide, all given weekly by subcutaneous injection. Most patients were very obese, with BMI values averaging 40.4 at baseline; body weight averaged 113 kg (249 lbs). Some 63% of participants were women; two-thirds were white and most of the rest were members of North American indigenous groups.
Importantly, a fairly aggressive lifestyle modification was urged on all participants. It included individualized dietary counseling and a program to encourage physical activity totalling at least 150 minutes/week. This helps to explain the weight loss and pain reductions seen in the placebo group.
WOMAC pain scores -- the study's co-primary outcome measure -- averaged 5.95 at baseline. By week 68, mean scores had fallen by 4.48 with the 9-mg dose and 4.41 points with 12 mg. Conaghan emphasized that 64% of participants had Kellgren-Lawrence OA grades of 3, reflecting substantial joint damage, making this degree of pain relief all the more remarkable.
Weight loss served as the other primary outcome, and it was equally dramatic. Already at week 8, both of the retatrutide groups had average losses approaching 7% (versus about 2% in the placebo arm), and losses grew through week 68 without reaching an obvious plateau (Indeed, some patients withdrew from the trial because they considered the weight loss excessive).
Physical function as evaluated with WOMAC averaged 5.75 at baseline, and this too improved markedly with retatrutide: by 4.14 points with 9 mg and 4.20 points with 12 mg, compared with a 2.06-point decline with placebo (higher scores=worse disability).
Conaghan also enthused over a responder analysis, counting patients achieving 30%, 50%, and 70% reductions from baseline in WOMAC pain scores. Amazingly, about 70% of both retatrutide arms saw 70% improvement in pain versus 26% of the placebo group.
As expected from an ultra-potent drug targeting metabolic processes, blood lipid levels also improved significantly with retatrutide. This was true for triglycerides and non-HDL cholesterol; the agent had virtually no effect on HDL cholesterol. Another encouraging finding was that the active drug cut high-sensitivity C-reactive protein (CRP, reflecting systemic inflammation) levels by half versus a 25% reduction with placebo.
Retatrutide did come with a non-negligible side effect burden. About 13% of the 9-mg arm and 18% of those on 12 mg withdrew because of adverse events (AEs), compared with 4% of the placebo group. About 10% of both retatrutide groups experienced serious AEs versus 2% with placebo.
Gastrointestinal AEs were most common, and were expected based on the GLP-1 drug experience. But other types also occurred more frequently with retatrutide: fatigue, dizziness, headache, and urinary tract infections occurred at rates two to four times higher than with placebo. Increased skin sensitivity was also an issue with the drug, especially at the higher dose, affecting 12% of patients compared with none in the placebo group. Conaghan noted that AEs appeared to be most common among patients at the lower end of the obesity spectrum, with BMI values <35.
来源:MedPage Today · medpagetoday.com